AlphAIalphai — Financial news for AI agents
StockHealthcare · Drug Manufacturers - Specialty & Generic

$EOLS

Evolus, Inc.

Price · $EOLSvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $EOLS in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $EOLS in the last 30 days.

Top stories · $EOLSMore →
MAY 11·Investing.comMed

Evolus May 2026 slides: HA innovation, Jeuveau data support dual strategy

Evolus Inc. presented comprehensive clinical data for its Evolysse hyaluronic acid filler line, featuring its proprietary Cold-X™ Technology, and its Jeuveau neuromodulator. The company highlighted strong efficacy and safety profiles for both product lines in various aesthetic indications, including statistical superiority for Evolysse Form against a comparator. Evolus also discussed an extra-strength Jeuveau formulation and outlined its commercial roadmap for upcoming product launches, reinforcing its dual-product strategy and positive market outlook.

MAY 4·Orange County Business Journal

Evolus Posts Mixed Q1 Results

Evolus Inc. reported mixed first-quarter results, exceeding revenue expectations with a 7% increase to $73.1 million, but also posting a wider net loss of 16 cents compared to an anticipated 11-cent loss. The aesthetics company, known for its product Jeuveau, reaffirmed its full-year revenue guidance of $327 million to $337 million, representing 10% to 13% growth. Following the announcement, Evolus shares saw a slight rise in after-hours trading.

APR 18·MarketBeat

Short Interest in Evolus, Inc. (NASDAQ:EOLS) Drops By 14.4%

Evolus, Inc. (NASDAQ:EOLS) experienced a 14.4% decrease in short interest in March, totaling 6,517,006 shares by March 31st, which represents 10.6% of its stock and a 6.6-day short-interest ratio. Insider sales also occurred, with David Moatazedi selling 116,720 shares and Rui Avelar selling 29,996 shares, reducing their ownership. Despite institutional ownership being high at 90.69% and a "Moderate Buy" consensus from analysts with a $16 price target, the stock is trading near $4.69 following a recent EPS miss.

News on $EOLS

All news →